文献速递肿瘤 PET/CT

68Ga-FAPI-04 PET/CT在头颈部鳞状细胞癌中的表现:与18F-FDG PET/CT的前瞻性比较

The performance of 68Ga-FAPI-04 PET/CT in head and neck squamous cell carcinoma: a prospective comparison with 18F-FDG PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-02-20

这项前瞻性研究纳入77例组织学证实或高度怀疑头颈部鳞状细胞癌(HNSCC)患者,在一周内配对完成18F-FDG与68Ga-FAPI-04 PET/CT,用于初始分期(n=67)或再分期(n=10)。68Ga-FAPI-04在术前N分期评估中的特异度和准确度优于18F-FDG,并改变了部分患者的临床管理。

要点

  • 68Ga-FAPI-04与18F-FDG对原发肿瘤的检出率均为100%,对复发的检出率均为62.5%。
  • 在29例接受颈淋巴结清扫的患者中,68Ga-FAPI-04评估术前N分期的特异度和准确度优于18F-FDG。
  • 68Ga-FAPI-04 PET/CT使10例(10/61)患者的临床管理发生显著改变。

核心结论

  • 68Ga-FAPI-04在评估HNSCC患者术前N分期方面优于18F-FDG PET/CT。
  • 68Ga-FAPI-04 PET/CT在临床管理和治疗反应监测方面也显示出潜力。

研究设计与样本

  • 前瞻性研究,纳入77例组织学证实或高度怀疑HNSCC的患者。
  • 患者在一周内配对接受18F-FDG和68Ga-FAPI-04 PET/CT,其中初始分期67例、再分期10例。
  • 比较两种影像方法的诊断性能,尤其针对N分期;对配对阳性病灶评估SUVmax、SUVmean和靶本比(TBR)。
  • 探索68Ga-FAPI-04 PET/CT对管理决策的改变及部分病灶的FAP组织病理表达。

主要发现

  • 18F-FDG与68Ga-FAPI-04 PET/CT对原发肿瘤的检出率均为100%,对复发的检出率均为62.5%。
  • 在29例接受颈淋巴结清扫的患者中,基于患者分析,68Ga-FAPI-04评估术前N分期的特异度优于18F-FDG(p=0.031),准确度p=0.070。
  • 基于颈侧分析,68Ga-FAPI-04评估术前N分期的特异度(p=0.002)和准确度(p=0.006)均优于18F-FDG。
  • 基于颈部分区分析,68Ga-FAPI-04评估术前N分期的特异度和准确度均优于18F-FDG(p<0.001和p<0.001)。
  • 基于病灶分析,68Ga-FAPI-04检测到更多远处转移阳性病灶(25 vs 23),且SUVmax更高(7.99 ± 9.04 vs 3.62 ± 2.68,p=0.002)。

关键数值与推荐

  • 原发肿瘤检出率:18F-FDG为100%,68Ga-FAPI-04为100%。
  • 复发的检出率:18F-FDG为62.5%,68Ga-FAPI-04为62.5%。
  • 远处转移病灶数:68Ga-FAPI-04为25个,18F-FDG为23个。
  • 远处转移病灶SUVmax:68Ga-FAPI-04为7.99 ± 9.04,18F-FDG为3.62 ± 2.68(p=0.002)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study was designed to compare the performance of 68Ga-FAPI-04 and 18F-FDG PET/CT for initial staging and recurrence detection of head and neck squamous cell carcinoma (HNSCC). METHODS: Prospectively, 77 patients with histologically proven or highly suspected HNSCC underwent paired 18F-FDG and 68Ga-FAPI-04 PET/CT in a week for either initial staging (n = 67) or restaging (n = 10). The diagnostic performance was compared for the two imaging approaches, especially for N staging. SUVmax, SUVmean, and target-to-background ratio (TBR) were assessed for paired positive lesions. Furthermore, change in management by 68Ga-FAPI-04 PET/CT and histopathologic FAP expression of some lesions were explored. RESULTS: 18F-FDG and 68Ga-FAPI-04 PET/CT exhibited a comparable detection efficiency for primary tumor (100%) and recurrence (62.5%). In the twenty-nine patients receiving neck dissection, 68Ga-FAPI-04 PET/CT showed greater specificity and accuracy in evaluating preoperative N staging than 18F-FDG based on patient (p = 0.031 and p = 0.070), neck side (p = 0.002 and p = 0.006), and neck level (p < 0.001 and p < 0.001). As for distant metastasis, 68Ga-FAPI-04 PET/CT detected more positive lesions than 18F-FDG (25 vs 23) and with higher SUVmax (7.99 ± 9.04 vs 3.62 ± 2.68, p = 0.002) by lesion-based analysis. The type of neck dissection in 9 cases (9/33) was altered by 68Ga-FAPI-04. Overall, clinical management was significantly changed in 10 patients (10/61). Three patients had a follow-up 68Ga-FAPI-04 PET/CT post neoadjuvant therapy: One showed complete remission, and the others showed progression. The 68Ga-FAPI-04 uptake intensity was confirmed to be consistent with FAP expression. CONCLUSION: 68Ga-FAPI-04 outperforms 18F-FDG PET/CT in evaluating preoperative N staging in patients with HNSCC. Furthermore, 68Ga-FAPI-04 PET/CT also shows the potential in clinical management and monitoring response to treatment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jiang Y, Wen B, Li C, et al. The performance of 68Ga-FAPI-04 PET/CT in head and neck squamous cell carcinoma: a prospective comparison with 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2023. PMID: 36808001. doi:10.1007/s00259-023-06138-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。